Clinical & Preclinical Research Services in Saudi Arabia

Diagnostics Innovation Biotech Environment Testing Research Diagnostics Innovation Biotech
Diagnostics Innovation Biotech Environment Testing Research Diagnostics Innovation Biotech

Explore Our Services

Planning a preclinical or clinical program? Tell us the development stage, study objective, target geography and current vendor or site status.

Plan Your Research Program
Clinical and preclinical research services

Ariba & Mac supports sponsors with coordinated clinical and preclinical research services spanning safety and pharmacology studies, protocol development, CRO and site coordination, clinical operations, data management and regulatory documentation. Programs are structured around the development question the sponsor needs to answer and the evidence required for the next milestone.

Research programs often become expensive or delayed when protocol design, vendor selection, site readiness, safety oversight, data workflows and regulatory requirements are handled independently. Our role is to connect these workstreams through a defined study plan, responsibilities, documentation standards and sponsor oversight model.

For studies conducted in Saudi Arabia, planning must account for SFDA clinical-trial requirements, Good Clinical Practice, site readiness, ethics processes and participant protection. We integrate those local considerations with the target international pathway when a program is intended to support submissions in more than one market.

Clinical & Preclinical Research Services for Sponsors in Saudi Arabia

From early safety work to clinical execution, the objective is to generate credible, traceable evidence while maintaining participant safety, protocol compliance and regulatory-ready documentation.

  • Preclinical safety, toxicology and pharmacology program planning, including GLP and non-GLP study coordination where appropriate.
  • Bioanalytical method development, validation and laboratory coordination to support study endpoints and data quality.
  • Clinical development planning, protocol design, study synopsis and supporting scientific documentation.
  • CRO and clinical-site identification, feasibility review, qualification and study-startup coordination.
  • Clinical trial management and monitoring support across Phase I–IV programs, with risk-based oversight, issue escalation and quality-system support where required.
  • Data-management, statistical-analysis and study-documentation coordination with defined quality controls.
  • Clinical Study Reports and regulatory-dossier support for the applicable SFDA, FDA, EMA, MHRA, GHC, MENA or DRAP pathway.

Preclinical Strategy & Safety Evidence

Define the studies needed to characterize safety, pharmacology and exposure before a program advances to the next clinical or regulatory milestone.

Clinical Operations & Site Coordination

Coordinate CROs and trial sites around protocol requirements, startup activities, monitoring, documentation, timelines and sponsor communication.

Data, Safety & Regulatory Documentation

Maintain attention to participant safety, data integrity, traceability and the study records required for scientific review and regulatory use.

Clinical Research Process: Protocol, Site, CRO & Regulatory Coordination

The process starts with protocol and regulatory strategy, then moves into vendor/site activation and controlled execution with defined sponsor oversight, safety escalation and data-review checkpoints.

  • Align scientific objectives, endpoints, population, operational feasibility, ethics requirements and regulatory expectations before sites are activated.
  • Use clear governance for CROs and sites, including issue escalation, monitoring expectations, data review and documentation responsibilities.

1. Protocol, Feasibility & Regulatory Planning

Review the development objective, available evidence and target markets; define the study design, vendor/site requirements, essential documents and regulatory or ethics activities needed before execution.

2. Study Execution, Oversight & Closeout

Coordinate study startup and conduct, monitor quality and safety signals, manage data and documentation workflows, and organize the final study outputs for scientific and regulatory review.

Clinical Trial Oversight Across CROs, Sites & SFDA Workstreams

A clinical program can involve many independent organizations. Our differentiator is the coordination layer that keeps the protocol, sites, vendors, data, safety and regulatory documentation working toward the same sponsor objective.

CRO & Site Coordination

Partner selection, feasibility, responsibilities, timelines and escalation paths are defined so the sponsor has clearer visibility across external research teams.

Saudi + Global Regulatory Planning

Saudi study requirements can be considered alongside the evidence and documentation expected for other target authorities, reducing avoidable disconnects between local execution and global development strategy.

Ethics, Participant Safety & Data Quality

Informed consent, protocol adherence, safety reporting, source documentation and data quality remain core controls throughout the study lifecycle.

Clinical Research Quality, GCP & Traceable Decision-Making

Study scope, vendor responsibilities, safety processes, data workflows and regulatory assumptions are documented at the outset. We avoid promising approval or recruitment outcomes; those depend on the protocol, sites, participants, evidence, authority review and other factors outside a consultant’s control.

Authoritative Regulatory, Government & Academic Resources

For current official requirements, standards and sector guidance, consult the relevant authority directly. These independent external resources are provided for reference and do not imply affiliation or replace project-specific regulatory, legal or clinical advice.

  • SFDA Clinical Trials — Official Saudi information on clinical-trial evaluation, registration, monitoring, inspections and GCP/GLP expectations.
  • ClinicalTrials.gov — U.S. government database of publicly registered clinical studies and study records.
  • ICH Efficacy Guidelines — International harmonized guidance covering clinical safety, efficacy and Good Clinical Practice topics.

FAQs About Clinical & Preclinical Research in Saudi Arabia

Scope can include preclinical safety and pharmacology planning, bioanalytical work, protocol development, CRO/site coordination, monitoring, data and statistics coordination, study reports and regulatory documentation.

Yes. Saudi programs can be planned around applicable SFDA clinical-trial requirements, GCP, ethics/site processes and participant-safety expectations, with coordination for the wider development pathway where required.

Yes. We can support feasibility, qualification, proposal comparison, role definition and ongoing oversight for CROs and sites based on the protocol, patient population, geography and sponsor requirements.

Quality is built through protocol clarity, trained responsibilities, essential-document controls, monitoring, issue escalation, safety reporting and data-review processes aligned with the study risk and applicable GCP requirements.

Study complexity, protocol design, ethics and regulatory review, site activation, recruitment, follow-up duration, data cleaning and reporting all affect timelines. A realistic plan is prepared after feasibility and regulatory assumptions are reviewed.

A protocol or synopsis if available, product and development background, target population, intended countries, current regulatory status, preferred timelines and any CRO/site work already completed are useful starting materials.